Clinical trial
A Study of MK0364 in Obese Patients (0364-014)
NCT00131391 · Merck Sharp & Dohme LLC, Industry · Terminated
Key facts
| NCT number | NCT00131391 |
|---|---|
| Title | A Study of MK0364 in Obese Patients (0364-014) |
| Official title | A 2-Year Study (1-Year Weight Loss Followed by 1-Year Prevention of Weight Regain) to Assess the Safety, Tolerability and Efficacy of Taranabant (MK0364) in Obese Patients Followed by a 1-Year Extension |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Obesity |
| Intervention type | Drug |
| Interventions | Comparator: taranabant, Comparator: placebo |
| Enrollment | 2,400 |
| Start date | Jul 1, 2005 |
| Primary completion | Feb 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Aug 18, 2005 |
| Last update posted | Apr 3, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: